Vancouver, British Columbia, January 31/2023: Global Wellness Strategies Inc. (CSE:GWS) (Frankfurt O3X4) (OTCQB: GWSFF) (“Global” or the “Company”) announces Shanti Therapeutics MDMA Clinical Trial Update.
“I am excited to lead Shanti into 2023, as we try to solve the puzzle of pain with MDMA. We are fortunate that the US is leading the way with promising research results and growing popularity of psychedelics bringing greater exposure to old illicit drugs globally. Shanti means peace and our goals for 2023 is simply to help pain sufferers finally find a solution to their own inner peace. Join us and our shareholders and become a stakeholder.” said Meris Kott, CEO, Global Wellness Strategies Inc.
Global Wellness Strategies is pleased to announce we are securing our import partner for export to Australia of MDMA. PharmAla Biotech Holdings Inc. supply agreement was signed in February 2022 and they remain the supplier of the GMP MDMA.
The world-class medical advisory team is lead by world-renowned Dr. Sud Agarwal. His experience and expertise in the psychedelic industry will contribute significantly to our efforts as a co-founder of Shanti Therapeutics as well as the CEO of iNGENü, based in Melbourne, Australia who is engaged as the CRO (clinical research organization) by the Company to conduct clinical trials for Shanti Therapeutics. iNGENü, has secured near US$100m in research work alone for 2023, hoping to become one of the global leaders in psychedelic research. It is presently completing trials for companies treating depression, anxiety, trauma, and pain.
Shanti’s product suite of MDMA could be the Global Market Winner finding a solution to the chronic puzzle of pain. The protocol is a single center, randomized crossover study to investigate the efficacy of MDMA vs placebo in a model of experimental pain in healthy adults. Shanti has a targeted research pathway to clinical success, with strong proprietary protection under its already submitted patent providing a method for the treatment or prevention of pain. Global Wellness acquired Shanti Therapeutics in 2022 and all share issuances for the acquisition have been completed.
About Global Wellness Strategies:
Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare- related target companies.
Further information about the Company is available on www.SEDAR.com under the Company’s profile.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
